Epidermal growth factor receptor (Egfr); results of a 6 year follow-up study in operable breast cancer with emphasis on the node negative subgroup

British Journal of Cancer

Volumn 63, Issue 1, 1991, Pages 146-150

  Nicholson, S ^a   Richard, J ^b   Sainsbury, C ^b   Halcrow, P ^c   Kelly, P ^c   Angus, B ^d   Wright, C ^d   Henry, J ^d   Farndon, J R ^a   Harris, A L ^e  

^a BRISTOL ROYAL INFIRMARY   (United Kingdom)

^b HUDDERSFIELD ROYAL INFIRMARY   (United Kingdom)

^c Medical School   (Australia)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

^e CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BREAST CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; FOLLOW-UP STUDIES; HUMAN; MIDDLE AGE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSPECTIVE STUDIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; TIME FACTORS;

EID: 0026098831     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.1991.30     Document Type: Article

References (31)

1. BONADONNA, G., ROSSI, A. & VALAGUSSA, P. (1985). Adjuvant CMF chemotherapy in operable breast cancer: Ten years later. Lancet, 1, 976
2. BONADONNA, G. & VALAGUSSA, P. (1987). Current status of ad juvant chemotherapy for breast cancer. Seminars in Oncol., 14, 8
3. BREAST CANCER TRIALS COMMITTEE; SCOTTISH CANCER TRI ALS OFFICE (MRC), EDINBURGH (1987). Adjuvant tamoxifen in the management of operable breast disease: The Scottish trial. Lancet, 2, 171
4. CLARK, G. M., DRESSLER, L. G., OWENS, M. A., POUNDS, G., OLD- AKER, T. & MCGUIRE, W. L. (1989). Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N. Engl. J. Med., 320, 627
5. COOKE, T., SHIELDS, R., GEORGE, D., MAYNARD, P. & GRIFFITHS, K. (1979). Oestrogen receptors and prognosis in early breast cancer. Lancet, 1, 995
6. COX, D. R. (1972). Regression models and life tables. J. R. Stat. Soc. (B), 34, 187
7. CRAWFORD, D., COWANS, S., HYDER, S., MCMENAMIN, M., SMITH, D. & LEAKE, R. (1984). Tumour biopsies prior to oestrogen receptor measurement. Cancer Res., 44, 2348
8. ELSTON, C. W., GRESHAM, G. A., RAO, G. S. & 4 others (1982). The Cancer Research Campaign (King’s/Cambridge) trial for early breast cancer; clinicopathological aspects. Br. J. Cancer, 45, 655
9. FISHER, B., BAUER, M., WICKERHAM, L., REDMOND, C. K. & FISHER, E. R. (1983). Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer, an NSAPB update. Cancer, 52, 1551
10. FISHER, B., COSTRANTINO, J., REDMOND, C. & 17 others (1989a). A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen- receptor-positive tumours. N. Engl. J. Med., 320, 479
11. FISHER, B., REDMOND, C., DIMITROV, N. V. & 10 others (19896). A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumour. N. Engl. J. Med., 320, 473
12. FISHER, B., REDMOND, C., FISHER, E. & 12 others (1988). Relative worth of estrogen or progesterone receptor and pathologic char acteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project B-06. J. Clin. Oncol., 6, 1076
13. FISHER, B., REDMOND, C., FISHER, E. R. & WOLMARK, N. (1986). Systemic adjuvant therapy in treatment of primary operable breast cancer: National Surgical Adjuvant Breast and Bowel Project. Natl Cancer Inst. Monogr., 1, 35
14. FISHER, B., REDMOND, C. K., POISSON, R. & 12 others (1989c). Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N. Engl. J. Med., 320, 822
15. LEAKE, R. E., LAING, L., CALMAN, K. C., MACBETH, F. R., CRAWFORD, D. & SMITH, D. C. (1981). Oestrogen receptor status and endocrine therapy of breast cancers: response rates and status stability. Br. J. Cancer, 43, 59
16. LUDWIG BREAST CANCER STUDY GROUP (1989). Prolonged dis ease-free survival after one course of perioperative adjuvant chemotherapy for node-negative breast cancer. N. Engl. J. Med., 320, 491
17. MANSOUR, EG., GRAY, R., SHATILA, A H. & 5 others (1989). Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N. Engl. J. Med., 320, 485
18. NICHOLSON, S., HALCROW, P., SAINSBURY, J. R. C. & 4 others (1988a). Epidermal growth factor receptor (EGFr) status asso ciated with failure of primary endocrine therapy in elderly post menopausal patients with breast cancer. Br. J. Cancer, 58, 810
19. NICHOLSON, S., SAINSBURY, J. R. C., HALCROW, P., CHAMBERS, P., FARNDON, J. R. & HARRIS, A. L. (1989). Expression of epidermal growth factor receptors associated with lack of response to endocrine therapy in recurrent breast cancer. Lancet, i, 182
20. NICHOLSON, S., SAINSBURY, J. R. C., NEEDHAM, G. K., CHAMBERS, P., FARNDON, J. R. & HARRIS, A. L. (19886). Quantitative assays of epidermal growth factor receptor in human breast: Cut off points of clinical relevance. Int. J. Cancer, 42, 36
21. NOLVADEX ADJUVANT TRIAL ORGANISATION (1988). Controlled trial of tamoxifen as single adjuvant agent in the management of early breast cancer: analysis at eight years by ‘Nolvadex’ Adju vant Trial Organisation. Br. J. Cancer, 57, 608
22. PADMANABHAN, N., HOWELL, A. & RUBENS, R. (1986). Mechan isms of action of adjuvant chemotherapy in early breast cancer. Lancet, 2, 411
23. PEREZ, R., PASCUAL, M., MACIAS, A. & LAGE, A. (1984). Epidermal growth factor receptors in human breast cancer. Breast Cancer Res. Treat., 4, 189
24. PETO, R., PYKE, M. C. & ARMITAGE, N. E. (1977). Design and ana lysis of randomized clinical trials requiring prolonged observation of each patient. II Analysis and examples. Br. J. Cancer, 35, 1
25. RIOS, M. A., MACIAS, A., PEREZ, R., LAGE, A. & SKOOG, L. (1988). Receptors for epidermal growth factor and estrogen as predictors of relapse in patients with mammary carcinoma. Anticancer Res., 8, 173
26. SAINSBURY, J. R. C., FARNDON, J. R., NEEDHAM, G. K., MALCOLM, A. J. & HARRIS, A. L. (1987). Epidermal growth factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet, 1, 1398
27. SAINSBURY, J. R. C., SHERBERT, G. V., FARNDON, J. R. & HARRIS, A. L. (1985). Epidermal growth factor receptors and oestrogen receptors in human breast cancer. Lancet, 1, 364
28. SILVESTRINI, R., DIADONE, M. G. & GASPAIRINI, G. (1985). Cell kinetics as a persistent prognostic marker in node-negative breast cancer. Cancer, 56, 1982
29. SLAMON, D. J., CLARK, G. M., WONG, S. G., LEVIN, W. J., ULLRICH, A. & MCGUIRE, W. L. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu onco gene. Science, 235, 177
30. VALAGUSSA, P., BONADONNA, G. & VERONESI, U. (1978). Patterns of relapse and survival following radical mastectomy: Analysis of 716 consecutive patients. Cancer, 41, 1170
31. WRIGHT, C., ANGUS, B., NICHOLSON, S. & 6 others (1989). Expres sion of c-erbB-2 oncoprotein: a prognostic marker in human breast cancer. Cancer Res., 49, 2087